ArriVent BioPharma Inc. C... (AVBP)
NASDAQ: AVBP
· Real-Time Price · USD
19.54
0.92 (4.94%)
At close: Aug 15, 2025, 3:59 PM
19.58
0.20%
After-hours: Aug 15, 2025, 05:41 PM EDT
ArriVent BioPharma Common Stock Balance Sheet Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q1 2022 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Mar 31, 2022 |
Cash & Equivalents | 112.77M | 49.87M | 74.29M | 282.86M | 298.67M | 317.39M | 150.39M | 141.36M | 157.83M | -163.37M | 163.37M | n/a |
Short-Term Investments | 122.92M | 126.21M | 144.57M | n/a | n/a | n/a | n/a | 25M | 25M | 326.74M | n/a | n/a |
Long-Term Investments | 18.79M | 29.41M | 47.68M | n/a | n/a | n/a | n/a | 106K | n/a | n/a | n/a | n/a |
Other Long-Term Assets | 479K | 176K | 126K | 126K | 125K | 108K | 2.84M | 1.96M | 82K | -163.37M | 72K | -37.28M |
Receivables | 505K | 505K | 500K | 500K | 750K | 875K | 761K | 1.09M | 258K | n/a | 500K | n/a |
Inventory | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Current Assets | 13.96M | 9.2M | n/a | 8.59M | 8.35M | 8.18M | 8.69M | n/a | n/a | n/a | n/a | n/a |
Total Current Assets | 250.15M | 185.78M | 226.98M | 292.4M | 308.51M | 327.48M | 159.97M | 179.98M | 198.69M | 163.37M | 182.62M | 37.28M |
Property-Plant & Equipment | 85K | 120K | 154K | 187K | 219K | 250K | 291K | 44K | 76K | n/a | 139K | n/a |
Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 19.36M | 29.71M | 47.96M | 313K | 344K | 358K | 3.13M | 2.11M | 158K | -163.37M | 211K | -37.28M |
Total Assets | 269.51M | 215.5M | 274.94M | 292.71M | 308.86M | 327.84M | 163.1M | 182.09M | 198.84M | n/a | 182.83M | n/a |
Account Payables | 4.06M | 4.36M | 3.78M | 4.65M | 3.81M | 4.1M | 4.53M | 4.82M | 6.46M | n/a | 3.09M | n/a |
Deferred Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Short-Term Debt | 98K | 138K | 162K | 157K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Current Liabilities | 12.69M | 1.41M | 4M | -140K | 2.04M | n/a | n/a | n/a | n/a | n/a | 2.46M | n/a |
Total Current Liabilities | 19.64M | 12.95M | 17.27M | 15.16M | 12.1M | 9.98M | 11.62M | 10.1M | 12.81M | n/a | 8.36M | n/a |
Long-Term Debt | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Liabilities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -41.22M |
Total Long-Term Liabilities | n/a | n/a | 14K | 56K | 98K | 138K | 177K | 304.49M | n/a | n/a | 11K | -41.22M |
Total Liabilities | 19.64M | 12.95M | 17.29M | 15.22M | 12.2M | 10.12M | 11.8M | 10.1M | 12.81M | n/a | 8.37M | -41.22M |
Total Debt | 98K | 138K | 176K | 213K | 250K | 285K | 317K | 44K | 76K | n/a | 139K | n/a |
Common Stock | 4K | 4K | 3K | 3K | 3K | 3K | n/a | 4K | 4K | n/a | 4K | n/a |
Retained Earnings | -334.12M | -302.72M | -238.33M | -217.7M | -197.14M | -175.26M | -157.84M | -136.65M | -122.25M | n/a | -88.51M | n/a |
Comprehensive Income | -18K | -17K | -211K | n/a | 0.00 | n/a | n/a | -4K | -4K | -85.11M | -4K | -48.64M |
Shareholders Equity | 249.87M | 202.54M | 257.65M | 277.49M | 296.66M | 317.72M | 151.3M | 171.99M | 186.03M | 174.46M | 174.46M | 41.22M |
Total Investments | 141.72M | 155.63M | 192.25M | n/a | n/a | n/a | n/a | 25.11M | 25M | 326.74M | n/a | n/a |